This prospective study confirms that neoadjuvant endocrine therapy (NET) with letrozole is a clinically effective and biologically meaningful strategy for tumor downstaging in postmenopausal patients with HR+/HER2− early breast cancer. The gene discussed is HR; the disease is breast carcinoma.